Identifying Novel Pathways at the Interface of Immunity and Metabolism

We are committed to the discovery and development of first-in-class, oral therapeutics for patients with autoimmune diseases

Landos Biopharma is a clinical-stage biotechnology company developing oral therapeutics to treat autoimmune diseases. BT-11, Landos’ lead asset, is currently being studied in a Phase 2 trial in ulcerative colitis (UC), with plans to initiate an additional Phase 2 trial in Crohn’s disease (CD). BT-11 is a small molecule that targets novel pathways within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient side effect profile.

View More

Aiming to Bring Safer, More Effective Therapies to Patients with IBD

For chronic conditions such as inflammatory bowel disease, current treatments bear adverse side effects and impact on patients’ quality of life. Landos Biopharma’s translational research is focused on identifying more precise targets for treating ulcerative colitis and Crohn’s disease. Our therapeutic approach aims to enhance the treatment paradigm of debilitating autoimmune diseases by preventing or reducing patient susceptibility to infections and other side effects common with current therapies.

At Landos Biopharma, our mission is to be bold and uncover new mechanisms of treating autoimmune diseases.